Artal International Management S.A.
10% owner at Scholar Rock Holding; Director at CAVA Group; Director at Lexicon Pharmaceuticals.
- Rank
- 163rd of 809
- Companies held
- 4
- Largest holding
- SRRK, 42.1% of total
- Latest SEC filing
- Jun 15, 2026
- Listed but not counted
- $24.0M
What the $1.08B is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Scholar Rock Holding SRRK Common Stock | Directly | 9,059,507 | $50.37 | $456M | 42.1% | Form 4, Apr 28, 2023 |
| CAVA Group CAVA Common Stock | Directly | 6,507,990 | $51.23 | $333M | 30.8% | Form 4, Jun 15, 2026 |
| Lexicon Pharmaceuticals LXRX Common Stock | Indirectly (see filing footnote) | 175,156,062 | $1.67 | $293M | 27.0% | Form 4, Apr 30, 2026 |
| Crescent Biopharma CBIO Common Stock | Directly | 85,891 split-adjusted | $12.91 | $1.1M | 0.1% | Form 4, Feb 24, 2023 |
Share counts are the amounts Artal International Management S.A. reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Reported but not counted
These shares appear on Artal International Management S.A.'s filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.
| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals LXRX Common Stock | Indirectly (see filing footnote) Held by a company or fund the insider manages | 7,362,368 | $1.67 | $12.3M | — | Form 4, Feb 2, 2026 |
| Lexicon Pharmaceuticals LXRX Common Stock | Through Invus US Partners LLC Held by a company or fund the insider manages | 5,451,204 | $1.67 | $9.1M | — | Form 4, Feb 2, 2026 |
| Lexicon Pharmaceuticals LXRX Common Stock | Through Avicenna Life Sci Master Fund LP Held by a company or fund the insider manages | 1,538,462 | $1.67 | $2.6M | — | Form 4, Feb 2, 2026 |
Open-market trades, last 12 months
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 160 | Glencore International AG 10% owner, Bunge Global SA | $1.10B |
| 161 | MP 13 Ventures, LLC 10% owner, ImmunityBio | $1.09B |
| 162 | IDG-Accel China Capital GP II Associates Ltd. 10% owner, Circle Internet | $1.09B |
| 163 | Artal International Management S.A. 10% owner, Scholar Rock Holding | $1.08B |
| 164 | GEI Capital VII, LLC 10% owner, WESCO International | $1.07B |
| 165 | BX Vine Intermediate Holdco L.P. 10% owner, Expand Energy | $1.06B |
| 166 | T11 Hhc, LLC 10% owner, Hyatt Hotels | $1.06B |
Other Scholar Rock Holding insiders
All SRRK insiders- David Hallal$92.9MChief Executive Officer. #1576 overall
- Akshay Vaishnaw$31.8MPresident of R&D. #3321 overall
- Keith Woods$31.2MChief Operating Officer. #3664 overall
- Vikas Sinha$31.2MChief Financial Officer. #3543 overall
- Nagesh K. Mahanthappa$24.2MInterim CEO and President. #4491 overall
- Jay Backstrom$21.4MCHIEF EXECUTIVE OFFICER. #4910 overall
Questions
How much stock does Artal International Management S.A. own?
Artal International Management S.A. holds $1,083,351,167 in listed stock based on SEC filings and current prices, mostly Scholar Rock Holding (SRRK). That ranks 163rd on the Stock Rich List.
Is this Artal International Management S.A.'s net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Artal International Management S.A. last buy or sell stock?
The most recent open-market trade on file is a sale of 3,000,000 CAVA shares on Jun 15, 2026 at $90.30.
Files jointly with Raymond Debbane, SEC filer 1053905, SEC filer 1460840, SEC filer 1841311.